ZymoGenetics Snags $70M Payout From BMS For Phase II Start Of New Interferon
This article was originally published in The Pink Sheet Daily
Executive Summary
A trial will evaluate PEG-Interferon lambda - a drug Bristol includes among its "string of pearls" - versus Pegasys for the treatment of hepatitis C.
You may also be interested in...
From HCV Partner To Acquirer, BMS Makes $885 M Offer for ZymoGenetics
Ever since its pure-play biopharma strategy went into effect, Bristol-Myers Squibb has preferred buying biotechs it knows well. Hepatitis C development partner ZymoGenetics is no exception.
From HCV Partner To Acquirer, BMS Makes $885 M Offer for ZymoGenetics
Ever since its pure-play biopharma strategy went into effect, Bristol-Myers Squibb has preferred buying biotechs it knows well. Hepatitis C development partner ZymoGenetics is no exception.
Sponsors Caution Against Premature Expanded Access For Novel HCV Drugs
Early positive trial results for direct-acting antivirals for Hepatitis C, combined with the seriousness of the disease and unmet clinical need, make Hep C an obvious target for expanded access programs.